miR-638 suppresses cervical cancer progression by inhibiting NCAPG2 under the treatment of Tetrandrine
Min Wang1*, Kai Liu2*, Zhongming Zhou1 and Huizhuan Geng3
1Department of Gynecology, 2Department of Nuclear Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine and 3Department of Gynecology, First Clinical College, Hubei University of Chinese Medicine, Wuhan, Hubei, PR China
*These authors contributed equally to this work
Corresponding Author: Huizhuan Geng, Department of Gynecology, First Clinical College, Hubei University of Traditional Chinese Medicine, No. 16 Huangjiahu West Road, Hongshan District, Wuhan 430065, Hubei, PR China. e-mail: huizhuangeng@163.com
Summary. Background. The interaction of microRNA with Chinese herbal medicines is a promising therapeutic approach for prevention of cervical cancer.
Methods. Western blotting or qRT-PCR were carried out to identify the expression of NCAPG2 and miR-638. A tetrandrine (TET) cell model was used to explore the effects of miR-638 and its target gene NCAPG2 using CCK-8, transwell, wound healing, and western blot assays. Furthermore, luciferase activity assay was conducted to measure the interaction among TET, NCAPG2 and miR-638.
Results. Under TET treatment, Hela and SiHa cells exhibited repressed cell viability, migration, invasion, and epithelial-mesenchymal transition (EMT), and these effects were further enhanced by high expression of miR-638. In contrast, NCAPG2 expression was low in TET-treated cells and had an opposite effect to that of miR-638.
Conclusion. We highlighted that miR-638 suppresses cervical cancer progression by inhibiting NCAPG2 under tetrandrine treatment. Histol Histopathol 39, 497-509 (2024)
Key words: miR-638, NCAPG2, Tetrandrine, Cervical cancer
DOI: 10.14670/HH-18-657
 |
ŠThe Author(s) 2024. Open Access. This article is licensed under a Creative Commons CC-BY International License. |
